- Enquiries into Nanoveu’s (NVU) suite of antiviral protection technologies are continuing to develop momentum
- Nanoveu’s flagship antiviral tech, Nanoshield, has demonstrated to be highly effective at eradicating viruses
- Nanoveu has signed an exclusive distribution agreement has signed with Vital Medikal for distribution in the Republic of Turkey
- The agreement between the parties is effective immediately over a 12-month term, with the ability to extend the agreement should all sales targets met
- Nanoveu has also signed a non-exclusive distribution agreement for Hong Kong with Asia Pro Lab for a 12-month term
- Nanoveu shares are up 14 per cent, trading at 5.7 cents
